TEVA PHARMACEUTICAL INDUSTRIES LTD 8-K

What Happened

• Teva Pharmaceutical Industries Ltd. announced on Jan 11, 2026 that it issued a press release setting out the company’s expectations for fiscal year 2025. The release was issued in connection with Teva’s presentation at the 44th Annual J.P. Morgan Healthcare Conference on Jan 13, 2026.
• The press release is furnished as Exhibit 99.1 to the Form 8‑K (filed Jan 12, 2026) and is incorporated by reference into the filing. The 8‑K was signed by Eli Kalif, Executive Vice President and Chief Financial Officer, dated Jan 11, 2026.

Key Details

• Date of press release: January 11, 2026.
• Conference presentation date: January 13, 2026 (44th Annual J.P. Morgan Healthcare Conference).
• Exhibit included: Exhibit 99.1 — press release titled “Teva to Present at the 44th Annual J.P. Morgan Healthcare Conference: Pivot to Growth Strategy Delivers Growth and Transforms through Innovation.”
• Item reported: 2.02 (Results of Operations and Financial Condition); the filing furnishes the press release (no full financial statements included).

Why It Matters

• The filing provides Teva’s public expectations for fiscal 2025 ahead of its investor presentation, giving shareholders and analysts updated guidance and context for the company’s near‑term performance.
• Investors should review the attached Exhibit 99.1 (the press release) and the conference presentation for the specific metrics and guidance disclosed, as those details drive modeling and near‑term market expectations.